FDA 483 - H. Henry Li, MD - March 24, 2023

An FDA inspection of Huamin Henry Li, M.D., Clinical Investigator, revealed a significant deficiency in obtaining informed consent for pediatric clinical subjects. The investigator failed to consistently secure the required signatures from both parents, despite IRB stipulations. This issue affected all 24 enrolled pediatric subjects in a clinical investigation involving children.